Moreover, a recent study highlighted the potentially deleterious effect of activated ERK in NE tumors by demonstrating that loss of ERK2 and negative ERK2 expression are specific features of the neuroendocrine carcinoma component of gastric mixed adenoneuroendocrine carcinoma (Sun et al., 2020). This evidence concerns the gene MAPK1 and neuroendocrine carcinoma.